Anthony Cerami

Attachments

1766-Today Rutgers University
1782-Today Harvard Medical School (HMS)
1863-Today National Academy of Sciences (NAS)
1901-Today Rockefeller University
1929-Today Jackson Laboratory (JAX)
1970-Today National Academy of Medicine (NAM)
Drug researchers
Kenneth S. Warren Institute
Professor and Head of the Laboratory of Medical Biochemistry, and Dean of Graduate and Postgraduate Studies at Rockefeller
Rockefeller and cancer links
Rockefeller and diseases links
Rockefeller University faculty
Vaccine Research and its links to Biological Weapons Research

1985 Cerami published in 1985 using polyclonal antibodies against tumour necrosis factor-alpha was important in the field of immunology for demonstrating that TNF-alpha causes disease and blocking it could be a treatment.
1989 Cerami was one of 15 Rockefeller faculty who vocally opposed the appointment of David Baltimore as president of Rockefeller in 1989.
1991-2001 Picower Institute for Medical Research
2001-2007 At the Warren institutes, Cerami led work on erythropoietin derivatives that were called "tissue protective cytokines", this work was licensed to Warren Pharmaceuticals and through them to Lundbeck in 2001, the development program was terminated
Alteon Inc.
Cerami developed and validated a measurement of glycated hemoglobin to monitor control of blood sugar in people with diabetes.
Cerami has led research programs into genetic, metabolic and infectious diseases, with the goal of translating scientific discovery into drugs and diagnostic tests.
Cerami received funding from the Rockefeller Foundation to study neglected tropical diseases and traveled to Africa, where he became interested in the wasting, one of the symptoms of African sleeping sickness.
Work that Cerami did while he was at Rockefeller on advanced glycation end-products (AGEs) and protein cross-linking and their roles in metabolic diseases and aging was patented by Rockfeller and licensed to Alteon Inc. ...